Seminars in Oncology Nursing
Volume 20, Issue 1 , Pages 3-10 , February 2004

Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis

  • Elenir B.C. Avritscher

      Affiliations

    • Section of Health Services Research, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • Corresponding Author InformationAddress request reprints to Elenir B.C. Avritscher, MD, MBA/MHA, Section of Health Services Research-Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd-Unit 196, Houston, TX 77030-4009, USA
    • ,
  • Catherine D. Cooksley

      Affiliations

    • Section of Health Services Research, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Linda S. Elting

      Affiliations

    • Section of Health Services Research, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

References 

  1. Sonis ST. Mucositis as a biological process (a new hypothesis for the development of chemotherapy-induced stomatotoxicity). Oral Oncology. 1998;34:39–43
  2. Trotti A, Bellm LA, Epstein JB, et al.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy (a systematic literature review). Radiother Oncol. 2003;66:253–262
  3. Murray JC, Chiu JK, Dorfman SR, et al.  Epiglottitis following preparation for allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;6:997–998
  4. Ruescher TJ, Sodeifi A, Scrivani SJ, et al.  The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82:2275–2281
  5. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci (a case-control study of predisposing factors). Clin Infect Dis. 1992;14:1201–1207
  6. Trotti A. Toxicity in head and neck cancer (a review of trends and issues). Int J Radiat Oncol Biol Phys. 2000;47:1–12
  7. Nicolaou N. Prevention and management of radiation toxicity. In:  Pazdur R,  Coia LR,  Hoskins WJ,  Wagman LD editor. Cancer Management (A Multidisciplinary Approach). New York, NY: SCP Oncology; 2003;p. 909–939
  8. Maguire A, Welbury RR. Long-term effects of antineoplastic chemotherapy and radiotherapy on dental development. Dent Update. 1996;23:188–194
  9. Bellm LA, Cunningham G, Durnell L, et al.  Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis (oral mucositis patient provider advisory board). Cancer Invest. 2002;20:793–800
  10. Elting LS, Cooksley C, Chambers M, et al.  The burdens of cancer therapy (clinical and economic outcomes of chemotherapy-induced mucositis). Cancer. 2003;98:1531–1539
  11. Sonis ST, Oster G, Fuchs H, et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–2205
  12. Peterman A, Cella D, Glandon G, et al.  Mucositis in head and neck cancer (economic and quality-of-life outcomes). J Natl Cancer Inst Monogr. 2001;29:45–51
  13. Sonis ST, Sonis Al, Lieberman A. Oral complications in patients receiving treatment for malignancy other than the head and neck. J Am Dent Assoc. 1978;97:468–472
  14. Cheng KKF, Molassiotis A, Chang AM, et al.  Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer. 2001;37:2056–2063
  15. Graham KM, Pecoraro DA, Ventura M, et al.  Reducing the incidence of stomatitis using a quality assessment and improvement approach. Cancer Nurs. 1993;16:117–122
  16. Sonis ST, Fey EG. Oral complications of cancer therapy. Oncology (Huntingt). 2002;16:680–686
  17. Rocke LK, Loprinzi CL, Lee JK, et al.  A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer. 1993;72:2234–2238
  18. McCarthy GM, Awde JD, Ghandi H, et al.  Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol. 1998;34:484–490
  19. Raber-Durlacher JE, Weijl NI, Abu Saris M, et al.  Oral mucositis in patients treated with chemotherapy for solid tumors (a retrospective analysis of 150 cases). Support Care Cancer. 2000;8:366–371
  20. Balducci L, Extermann M. Management of cancer in the older person (a practical approach). Oncologist. 2000;5:224–237
  21. Fidler P, Loprinzini CL, O’Fallon JR, et al.  Prospective evaluation of chamomile mouthwash for prevention of 5-fu-induced oral mucositis. Cancer. 1996;77:522–526
  22. Okuno SH, Woodhouse CO, Loprinzi CL, et al.  Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol. 1999;22:258–261
  23. Sloan JA, Loprizini CL, Novotny PJ, et al.  Sex differences in fluorouracil-induced stomatitis. J Clin Oncol. 2000;18:412–420
  24. Sloan JA, Goldberg RM, Sargent DJ, et al.  Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20:1491–1498
  25. Peterson DE, Minah GE, Overholser CD, et al.  Microbiology of acute periodontal infection in myelosuppressed cancer patients. J Clin Oncol. 1987;5:1461–1468
  26. Borowski B, Benhamou E, Pico JL, et al.  Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation (a randomised controlled trial comparing two protocols of dental care). Eur J Cancer B Oral Oncol. 1994;30B:93–97
  27. Raber-Durlacher JE. Current practices for management of oral mucositis in cancer patients. Support Care Cancer. 1999;7:71–74
  28. Berger AM, Eilers J. Factors influencing oral cavity status during high-dose antineoplastic therapy (a secondary data analysis). Oncol Nurs Forum. 1998;25:1623–1626
  29. McGuire DB. Mucosal tissue injury in cancer therapy. More than mucositis and mouthwash. Cancer Pract. 2002;10:179–191
  30. Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 1998;25:538–551
  31. Epstein JB, Tsang AH, Warkentin D, et al.  The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis (a review of the literature). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:39–44
  32. Pico JL, Avila-Garavito A, Naccache P. Mucositis (Its occurrence, consequences, and treatment in the oncology setting). Oncologist. 1998;3:446–451
  33. Barbounis V, Koumakis G, Vassilomanolakis M, et al.  Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer. 2001;9:258–260
  34. Rougier P, Bugat R, Douillard JY, et al.  Phase ii study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251–260
  35. Peterson DE. Research advances in oral mucositis. Curr Opin Oncol. 1999;11:261–266
  36. Hansen RM, Ryan L, Anderson T, et al.  Phase iii study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst. 1996;88:668–674
  37. Anonymous . Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-analysis group in cancer. J Clin Oncol. 1998;16:3537–3541
  38. Codacci-Pisanelli G, Van der Wilt CL, Smid K, et al.  High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into rna in murine tumors. Oncology. 2002;62:363–370
  39. Bellm LA, Epstein JB, Rose-Ped A, et al.  Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8:33–39
  40. Hoekman K, Vermorken JB. Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Ann Med. 1996;28:175–182
  41. McGlave PB, Shu XO, Wen W, et al.  Unrelated donor marrow transplantation for chronic myelogenous leukemia (9 years’ experience of the national marrow donor program). Blood. 2000;95:2219–2225
  42. Rapoport AP, Miller Watelet LF, Linder T, et al.  Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 1999;17:2446–2453
  43. National Institutes of Health Consensus Development Panel . Consensus statement (Oral complications of cancer therapies). In: National Cancer Institute monographs. Bethesda, MD: US Department of Health and Human Service, Public Health Service National Cancer Institute; 1990;p. 3–8
  44. Zerbe MB, Parkerson SG, Ortlieb ML, et al.  Relationships between oral mucositis and treatment variables in bone marrow transplant patients. Cancer Nurs. 1992;15:196–205
  45. Woo SB, Sonis ST, Monopoli MM, et al.  A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72:1612–1617

PII: S0749-2081(03)00133-5

doi: 10.1053/j.soncn.2003.10.002

Seminars in Oncology Nursing
Volume 20, Issue 1 , Pages 3-10 , February 2004

Article Tools